GET DAILY SIGNALSWhy Is Neumora Therapeutics (NMRA) Stock Down -7.72% Today?
Key Takeaways
- Shares of NMRA fell about 7.7% on Friday, trading near $0.37 versus a prior close of $0.41.
- The primary catalyst was an FDA clinical hold placed on the company's Phase 1 study of NMRA-266 for certain neuropsychiatric disorders.
- The setback compounds lingering pressure from the 2025–2026 failure of its lead depression program, navacaprant, which was ultimately discontinued.
- The decline reflects broader risk-off sentiment toward micro-cap, pre-revenue biotech names with thin clinical pipelines.
- Traders are watching next for the resolution of the clinical hold and upcoming data readouts from NMRA-898 and NMRA-511.
- For a deeper look at analyst targets, results, and projections, explore the detailed Price Targets, Earnings, and Forecast pages.
- See how automated strategies are trading this and other symbols on the Trending AI Robots page.
Opening Summary
Neumora Therapeutics, Inc. (NMRA) is a Watertown, Massachusetts-based clinical-stage biopharmaceutical company developing brain-penetrant medicines for neuropsychiatric, neurodegenerative, and metabolic diseases. In Friday's session, the stock declined roughly 7.7%, last trading near $0.37 after closing the prior session at $0.41. The selling was driven by news that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the company's Phase 1 study of NMRA-266, an investigational therapy being evaluated in certain neuropsychiatric conditions.
FDA Clinical Hold on NMRA-266
The sharpest driver of the market reaction was the disclosure of an FDA clinical hold affecting the Phase 1 program for NMRA-266. Regulatory holds of this nature pause patient enrollment and dosing, raising near-term uncertainty about a program's timeline and viability. For a pre-revenue company whose valuation rests almost entirely on its pipeline, any regulatory setback tends to be priced in aggressively, and NMRA shares fell on the announcement.
Pipeline Setbacks Linger as a Backdrop
The clinical-hold news landed on a stock already under sustained pressure. Neumora's lead asset, navacaprant, failed to meet primary and key secondary endpoints in the Phase 3 KOASTAL program in major depressive disorder, prompting the company to discontinue the asset and cut roughly 35% of its workforce. That failure sharply reset investor expectations, leaving the company's valuation dependent on earlier-stage candidates such as NMRA-511 for Alzheimer's disease agitation and NMRA-898 for schizophrenia. Against that backdrop, the NMRA-266 hold amplified existing skepticism about the breadth and durability of the remaining pipeline.
Market Context and Trading Activity
The move reflects the heightened volatility typical of micro-cap biotech equities trading well below their 52-week highs. NMRA has fallen from a 52-week high near $3.65 to a range near $0.37, and its market capitalization has compressed to a small fraction of its earlier levels. With no commercial revenue and a cash position intended to fund operations into the third quarter of 2027, the stock remains highly sensitive to individual clinical and regulatory headlines rather than broad index trends. The decline was company-specific, diverging from the performance of larger healthcare indices.
What Comes Next for NMRA
Investors will be watching for any clarification from the company on the NMRA-266 hold, including the specific safety or regulatory issues cited by the FDA and the pathway to resuming the trial. Attention also remains on upcoming catalysts across the rest of the pipeline, including data for NMRA-898 and NMRA-511, which represent the near-term drivers of the investment thesis. Risks remain substantial: the company is loss-making, pre-revenue, and exposed to binary clinical outcomes, and its ability to preserve capital while advancing multiple programs will be closely scrutinized.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore automated approaches tailored to different market environments. If you are looking to complement your own research with data-driven trading signals, consider reviewing the Trending AI Robots page today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NMRA saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for NMRA moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 35 similar instances where the indicator exited the overbought zone. In 34 of the 35 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NMRA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 18 of 20 cases over the following month. The odds of a continued upward trend are 90%.
Following a +33.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.712) is normal, around the industry mean (2.973). P/E Ratio (-0.330) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement